• In June 2026, AnaptysBio, Inc. was removed from several Russell indices, including the Russell Microcap, Russell 3000E, and related growth benchmark indices, triggering index rebalancing by passive funds.
• This broad removal from key Russell benchmarks may influence how investors perceive AnaptysBio’s visibility, liquidity, and role within the small-cap biotech universe.
• We’ll now examine how AnaptysBio’s exit from multiple Russell indices shapes its investment narrative, especially around index-driven ownership and liquidity.

Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is AnaptysBio's Investment Narrative?

For someone owning AnaptysBio, the real thesis still revolves around its immunology pipeline, royalty assets and progress on the GSK/Vanda collaborations, rather than its index membership. The recent removal from multiple Russell indices could affect near term trading liquidity and passive fund ownership, but the stock’s very large 1‑year total return and sharp 30‑day move suggest active investors are already driving the story. Near term, the bigger swing factors look like the Jemperli litigation outcome, clarity on the First Tracks spin‑off and how the new CFO and refreshed board execute on capital allocation, including the US$100 million buyback. Index exclusion may marginally raise volatility or widen spreads, but it does not change the core clinical, legal and execution risks that still define the business.

However, the ongoing Jemperli litigation could materially reshape AnaptysBio’s royalty profile and cash generation. Despite retreating, AnaptysBio's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Three Simply Wall St Community fair value views span roughly US$87 million to US$386.52 million, highlighting wide disagreement, while the recent Russell index exit adds another layer of uncertainty for AnaptysBio’s future liquidity and execution.

Explore 3 other fair value estimates on AnaptysBio - why the stock might be worth over 5x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AnaptysBio research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free AnaptysBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AnaptysBio's overall financial health at a glance.

Curious About Other Options?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.